

Special Issue

Bluetongue, Epizootic Haemorrhagic Disease, and Other Emerging Orbiviruses, 2nd Edition

Message from the Guest Editor

The recent emergence of Bluetongue virus serotype 3 (BTV-3) in Europe and the expanding distribution of Epizootic Haemorrhagic Disease virus (EHDV) highlight the ongoing challenges posed by emerging orbiviruses worldwide. These vector-borne pathogens continue to threaten livestock and wildlife, with potentially severe economic and ecological consequences. This special issue aims to gather cutting-edge research focused on various aspects of orbivirus biology, including molecular characterization, epidemiology, pathogenesis, diagnostic advancements, vaccination strategies, and disease control. Studies addressing novel orbiviruses, their ecological and evolutionary dynamics, as well as innovative approaches to surveillance and outbreak response, are particularly welcome. By providing an updated and comprehensive overview of orbivirus research, this issue seeks to contribute to the development of effective control and prevention measures.

Guest Editor

Dr. Ludovic Martinelle

CARE-FEPEX Experimental Station, Fundamental and Applied Research for Animals & Health (FARAH) Center, Faculty of Veterinary Medicine, University of Liege, 4000 Liege, Belgium

Deadline for manuscript submissions

31 December 2026



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/236461

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).